These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 20702974)

  • 1. Pravastatin potentiates increases in serum adiponectin concentration in dyslipidemic patients receiving thiazolidinedione: the DOLPHIN study.
    Nezu U; Tsunoda S; Yoshimura H; Kuwabara T; Tomura S; Seki Y; Kaneshiro M; Kamiyama H; Harada Y; Shigematsu E; Aoki K; Yamakawa T; Ohshige K; Natsumeda Y; Terauchi Y
    J Atheroscler Thromb; 2010 Oct; 17(10):1063-9. PubMed ID: 20702974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of 6 months of treatment with pravastatin on serum adiponection concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study.
    Sakamoto K; Sakamoto T; Ogawa H;
    Clin Ther; 2006 Jul; 28(7):1012-21. PubMed ID: 16990079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effect of lipophilic and hydrophilic statins on serum adiponectin levels in patients with mild hypertension and dyslipidemia: Kinki Adiponectin Interventional (KAI) Study.
    Kai T; Arima S; Taniyama Y; Nakabou M; Kanamasa K
    Clin Exp Hypertens; 2008 Oct; 30(7):530-40. PubMed ID: 18855257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of increasing the dose of pravastatin on serum adiponectin level in Japanese mild hypercholesterolemic and hypertensive patients.
    Kai T; Kanamasa K
    Arzneimittelforschung; 2009; 59(9):445-50. PubMed ID: 19856791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087.
    Fichtenbaum CJ; Yeh TM; Evans SR; Aberg JA
    J Clin Lipidol; 2010; 4(4):279-87. PubMed ID: 20824151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pravastatin on serum adiponectin levels in female patients with type 2 diabetes mellitus.
    Kim JH; Lee MR; Shin JA; Lee SS; Lee JM; You SJ; Yoon KH; Chang SA
    Atherosclerosis; 2013 Apr; 227(2):355-9. PubMed ID: 23466100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
    Sponseller CA; Morgan RE; Kryzhanovski VA; Campbell SE; Davidson MH
    Clin Ther; 2014 Aug; 36(8):1211-22. PubMed ID: 24998014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Greater remnant lipoprotein cholesterol reduction with pitavastatin compared with pravastatin in HIV-infected patients.
    Joshi PH; Miller PE; Martin SS; Jones SR; Massaro JM; D'Agostino RB; Kulkarni KR; Sponseller C; Toth PP
    AIDS; 2017 Apr; 31(7):965-971. PubMed ID: 28121706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
    LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
    Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study.
    Kushiro T; Mizuno K; Nakaya N; Ohashi Y; Tajima N; Teramoto T; Uchiyama S; Nakamura H;
    Hypertension; 2009 Feb; 53(2):135-41. PubMed ID: 19104004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to preferable behavior for lipid control by high-risk dyslipidemic Japanese patients under pravastatin treatment: the APPROACH-J study.
    Kitagawa Y; Teramoto T; Daida H;
    J Atheroscler Thromb; 2012; 19(9):795-805. PubMed ID: 23006830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin.
    Arnaboldi L; Corsini A
    Atheroscler Suppl; 2015 Jan; 16():1-27. PubMed ID: 25575403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pravastatin improves insulin resistance in dyslipidemic patients.
    Okada K; Maeda N; Kikuchi K; Tatsukawa M; Sawayama Y; Hayashi J
    J Atheroscler Thromb; 2005; 12(6):322-9. PubMed ID: 16394616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data.
    Bell KJ; Kirby A; Hayen A; Irwig L; Glasziou P
    BMJ; 2011 Jan; 342():d12. PubMed ID: 21257657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial.
    Aslangul E; Assoumou L; Bittar R; Valantin MA; Kalmykova O; Peytavin G; Fiévet MH; Boccara F; Bonnefont-Rousselot D; Melchior JC; Giral P; Costagliola D
    AIDS; 2010 Jan; 24(1):77-83. PubMed ID: 19838098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: a post hoc analysis of the MEGA Study.
    Nishiwaki M; Ikewaki K; Ayaori M; Mizuno K; Ohashi Y; Ohsuzu F; Ishikawa T; Nakamura H;
    J Cardiol; 2013 Mar; 61(3):196-200. PubMed ID: 23265677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease.
    Sugiyama S; Fukushima H; Kugiyama K; Maruyoshi H; Kojima S; Funahashi T; Sakamoto T; Horibata Y; Watanabe K; Koga H; Sugamura K; Otsuka F; Shimomura I; Ogawa H
    Atherosclerosis; 2007 Oct; 194(2):e43-51. PubMed ID: 17112529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.